RedHill Biopharma Ltd. is an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary formulations and combinations of existing drugs for the treatment of inflammatory and gastrointestinal diseases, including cancer and related conditions. In particular, RedHill’s development pipeline includes two potential blockbusters currently in Phase III studies in the U.S. for the treatment of gastrointestinal conditions: RHB-104 for the treatment of Crohn’s and RHB-105 for H. pylori infection. Major institutional investors include OrbiMed and Broadfin. Cash as of March 31, 2014 was approximately $38 million, with no debt. In February 2014, RedHill partnered RHB-106, an encapsulated bowel prep and related rights, with Salix Pharmaceuticals (SLXP), in return for a $7 million upfront payment as well as future milestone and royalty payments.
RedHill’s current pipeline of proprietary products includes: (i) RHB-104 - an oral combination therapy for the treatment of Crohn's disease, with an ongoing Phase III study; (ii) RHB-105 - an oral combination therapy for Helicobacter pylori infection, with an ongoing Phase III study; (iii) RHB-106 - an encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals Ltd. (SLXP); (iv) RHB-103 - an oral thin film formulation of rizatriptan for acute migraines with a U.S. NDA under FDA review and a planned European marketing application; (v) RHB-102 - a once-daily oral pill formulation of ondansetron for the prevention of nausea and vomiting, in advanced development stages for multiple indications and, (vi) RHB-101 - a once-daily oral pill formulation of the cardio drug carvedilol.Find a broker to begin trading RDHL now
|Company Name||RedHill Biopharma|
|Avg. Daily Vol. (3m)||53,493|
|As of Jan. 16, 2017|